We are Aidence: we rally the brightest minds to drastically improve medical diagnostics using AI
Our team consists of data science, medical and regulatory experts, supported by a talented team of professionals, experienced advisors, and critical users.
Together we built Veye Lung Nodules and Veye Reporting, our first AI clinical applications for early lung cancer diagnosis and reporting.
We provide intelligent software that empowers healthcare and pharmaceutical professionals to deliver faster, more precise diagnostics and treatments.
Data is key to improve the prevention, management, and treatment of diseases.
Founded in Amsterdam by Mark-Jan Harte and Jeroen van Duffelen
Top algorithm in Kaggle challenge
CE Mark for Veye Lung Nodules
€10M series A investment
One of the first to renew CE mark under new EU Medical Device Regulation
Set-up a consortium to develop a Covid-19 solution, backed by the EU
NHSx AI award (Phase 4) to improve lung cancer prognosis in the UK
€714k grant to expand lung nodule solution, in partnership with Erasmus MC and The Netherlands Cancer Institute
Collaboration with AstraZeneca to support early lung cancer diagnosis using AI
Preferred partner for the NHS England Targeted Lung Health Checks (lung cancer screening programme)
Expand the suite of chest applications to tumours and coronary artery calcification.
Augment oncology pathways with solutions for patient follow-up and multidisciplinary team meetings (MDTs).
AI in Health and Care Award Phase 4 (2020)
UCSF Digital Health Awards, “Best digital health product or service for enabling better mental & behavioral health and wellness” (2019)
Kaggle DataScience Bowl “Can you improve lung cancer detection?” (2017)
Our purpose is to improve people’s lives, from caregiver to patient.
We’re in a hyped industry, but we never exaggerate our capabilities.
We deliver what we promise, on time.
We encourage all stakeholders to speak openly and share their ideas.
We perfect one product before building the next and never stop improving.